Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDQ443 in Advanced Solid Tumors with KRAS G12C Mutation
NCT04699188Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of opnurasib in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (4 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 24 months and 4 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04699188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699188.